Lonza and Odyssey Thera, Inc. have signed an agreement under which Lonza will make Odyssey’s Protein-fragment Complementation Assay (PCA) technology, as part of compound profiling services, available to life science researchers. Additionally, Lonza has an option to certain exclusive global technology licenses. The companies have also initiated collaborative technology, product development and marketing activities. Odyssey will also receive an equity investment, making Lonza a minority ...